Caristo has announced that a study demonstrating that its AI CaRi-Heart technology can predict cardiac events due to coronary inflammation at least ten years in advance has been published.
Caristo’s CaRi-Heart technology is an AI-assisted diagnostics and risk prediction tool that is designed to support the diagnosis of coronary artery disease and offer an improved prediction of disease risk.
This analysis enables healthcare professionals to improve their patient’s cardiac risk evaluation for optimising medical management.
The CaRi-Heart risk score outperformed other clinical scores and changed management decisions in 45% of cases, targeting previously undetected coronary inflammation.
In April 2023, Caristo raised £13m ($16.3m) in a Series A financing round led by Oxford Science Enterprises to advance its CaRi-Heart technology.
According to GlobalData, there will be 51.8 million cases of heart failure globally by 2027. Credit: Ws Studio1985 via Shutterstock.
Caristo has announced that a study demonstrating that its AI CaRi-Heart technology can predict cardiac events due to coronary inflammation at least ten years in advance has been published.
Caristo’s CaRi-Heart technology is an AI-assisted diagnostics and risk prediction tool that is designed to support the diagnosis of coronary artery disease and offer an improved prediction of disease risk. It analyses cardiac computed tomography angiography (CCTA) scans of patients visiting rapid-access chest pain clinics. This analysis enables healthcare professionals to improve their patient’s cardiac risk evaluation for optimising medical management.
The data, published in The Lancet, shows that among patients undergoing CCTA, over 80% without obstructive CAD [coronary artery disease] experienced twice as many fatal and non-fatal cardiac events.
The CaRi-Heart FAI-score – which determines the risk of cardiac mortality caused by coronary inflammation – predicted these events independently of traditional risk factors and clinical assessments for up to ten years. The CaRi-Heart risk score outperformed other clinical scores and changed management decisions in 45% of cases, targeting previously undetected coronary inflammation.
The ORFAN study (NCT05169333) analysed results from the first 40,000 patients enrolled in the “ORFAN” registry, the world’s largest study that evaluates CCTA imaging biomarkers in predicting long-term cardiovascular outcomes, according to Caristo.
Caristo’s chief medical officer Keith Channon said: “Coronary inflammation is a crucial piece of the puzzle in predicting heart attack risk. We are excited to discover that CaRi-Heart results performed exceptionally well in predicting patient cardiac events. This tool is well positioned to help clinicians identify high-risk patients with seemingly ‘normal’ CCTA scans.”
How well do you really know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. View profiles in store Company Profile – free sample Thank you! Your download email will arrive shortly Not ready to buy yet? Download a free sample We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form By GlobalData Submit Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena. Submit and download Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
In April 2023, Caristo raised £13m ($16.3m) in a Series A financing round led by Oxford Science Enterprises to advance its CaRi-Heart technology. In July 2023, the company announced that it was deploying its CaRi-Heart technology in National Health Service (NHS) hospitals in the UK, as part of the new coronary artery disease management pathway pilot.
The use of AI to help detect heart problems is a growing sector. Earlier this month, HeartBeam presented data demonstrating that its HeartBeam AI applied to vectorcardiography technology outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter.
According to a report on GlobalData’s Pharma Intelligence Center, there will be over 51.8 million cases of heart failure globally in 2027.
GlobalData is the parent company of Clinical Trials Arena.
